Black Rock Inc. Lantern Pharma Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Black Rock Inc. holds 39,841 shares of LTRN stock, worth $139,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,841

Previous 19,659 102.66%

Holding current value

$139,443

Previous $172,000 8.14%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.91 - $9.51 $78,911 - $191,930	20,182 Added 102.66%	39,841 $186,000
Q1 2024 May 10, 2024	SELL	$3.73 - $10.65 $1,130 - $3,226	-303 Reduced 1.52%	19,659 $172,000
Q4 2023 Feb 13, 2024	SELL	$2.48 - $4.39 $461 - $816	-186 Reduced 0.92%	19,962 $85,000
Q3 2023 Nov 13, 2023	SELL	$3.41 - $5.51 $2,219 - $3,587	-651 Reduced 3.13%	20,148 $68,000
Q2 2023 Aug 11, 2023	SELL	$4.56 - $6.02 $2,968 - $3,919	-651 Reduced 3.03%	20,799 $117,000
Q1 2023 May 12, 2023	BUY	$4.3 - $6.2 $2,399 - $3,459	558 Added 2.67%	21,450 $103,000
Q4 2022 Feb 13, 2023	BUY	$4.19 - $6.04 $1,558 - $2,246	372 Added 1.81%	20,892 $126,000
Q3 2022 Nov 14, 2022	SELL	$4.59 - $6.5 $10,290 - $14,573	-2,242 Reduced 9.85%	20,520 $98,000
Q2 2022 Aug 12, 2022	SELL	$4.82 - $7.45 $1,503 - $2,324	-312 Reduced 1.35%	22,762 $129,000
Q1 2022 May 12, 2022	SELL	$5.6 - $8.22 $5,241 - $7,693	-936 Reduced 3.9%	23,074 $164,000
Q4 2021 Feb 10, 2022	BUY	$7.11 - $11.04 $6,654 - $10,333	936 Added 4.06%	24,010 $190,000
Q3 2021 Nov 09, 2021	SELL	$10.53 - $14.93 $21,512 - $30,501	-2,043 Reduced 8.13%	23,074 $258,000
Q2 2021 Aug 11, 2021	BUY	$12.94 - $19.89 $325,013 - $499,577	25,117 New	25,117 $366,000

Others Institutions Holding LTRN

# of Institutions

Shares Held

1.29M

Call Options Held

39.8K

Put Options Held

6.1K

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $37.9M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account